Kornimate/medical-research-clean huggingface dataset:
the interaction and regulation mechanism of different exercise patterns with metabolic syndrome and related metabolic diseases

Conditions: Obesity; Metabolic Syndrome

Summary: in order to obtain suitable exercise intervention model for children and adolescents with obese or metabolic syndrome in china, we conduct a rct to examine the effects of different intensity exercise intervention on weight, and other cardiometabolic risk factors among children and adolescents, we also test the effects of exercise interventions on multi-omics such as metabolomics, gut microbiome, genetics, and explore the potential mechanisms by which exercise interventions modulate cardiometabolic risk. this is a randomized controlled study. children and adolescents with obesity or metabolic syndrome were randomly divided into three groups, including low intensity exercise training group, moderate and intermittent high intensity exercise training group. the investigators will obtain organ hydrodynamics indexes by abdominal ultrasound and computational fluid dynamics technology, and obtain the metabolic regulation mechanism of the body in response to exercise through the detection of metabolism related small molecules in blood and urine and the analysis of intestinal flora, so as to explore the potential value and mechanism of different exercise modes in the treatment of obesity and metabolic syndrome. at the same time, the behavior and self-consciousness of children and adolescents will be investigated to obtain the suitable exercise intervention model for chinese children and adolescents with obesity and metabolic syndrome. in conclusion, this study aims to demonstrate which exercise mode can alleviate obesity or reverse metabolic diseases, analyze which factors can sense exercise, and explore the potential mechanisms through mutil-omic approach, so as to improve metabolic syndrome.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of overweight or obesity or metabolic syndrome; * good academic performance in school; * willing to sign informed consent. exclusion criteria: * clinical diagnosis of cushing syndrome; * pathological obesity such as prader-willi syndrome and obesity caused by drug factors； * participated in other intervention studies within the previous three months; * participant or their guardian has obvious intellectual or mental abnormalities.

Keywords: children and adolescents obesity metabolic syndrome overweight exercise
mobile-assisted case management for panic disorder

Conditions: Panic Disorder

Summary: a panic attack (pa) is an intense form of anxiety accompanied by multiple somatic presentations, leading to frequent emergency department visits and impairing quality of life. a prediction model for pas could help clinicians and patients monitor, control, and do early intervention for recurrent panic attacks, enabling more personalized treatment for panic disorder. this study aimed to provide a seven-day pa prediction model and determine the relationship between a future pa and various features, including physiological factors, anxiety and depressive factors, and air quality index. we will enroll 200 participants (150 participants join case management with wearables study, 50 participants join tau group) with pd (dms-5 and mini interview). participants used smartwatches (garmin vivosmart 4) and mobile applications to collect their sleep, heart rate, activity level, anxiety, and depression scores (bdi, bai, stai-s, stai-t, and pdss-sr) in their real-life for a duration of one year. we also included air quality indexes from open data. to analyze these data, our team used six machine learning methods: random forests, decision trees, lda, adaboost, xgboost, and regularized greedy forests, or other deep learning methods.

participants enrollment through primary psychiatrists' invitations, we will recruit 150 en chu kong hospital psychiatric clinic pd participants and 50 patients from mackay memorial hospital. inclusion criteria the inclusion criteria were 1) a primary diagnosis of pd by dsm-5, 2) more than 20 years old, and 3) an essential ability to navigate smartwatches and mobile phone applications. if participants did not fulfill criteria 3), we will invite them as the control group (i.e. tau) exclusion criteria the exclusion criteria were 1) current substance abuse, 2) cardiopulmonary incapacity, 3) incapacity or limited mental capacity, and 4) acute suicidal ideation. this study required sufficient mental capacity on the part of participants to cooperate by wearing smartwatches continuously, properly maintaining the smartwatches, and completing regular, valid online questionnaires. limited mental capacity implies that the participants have difficulties understanding, remembering, or using the information to make or communicate a decision. our team evaluated participants' mental capacity during the diagnostic interview (di), mini international neuropsychiatric interview (mini), and the informed consent process by certified psychiatrists and nurse practitioners. the information on acute suicidal ideation was from diagnostic interviews and questions from mini part a and pre-assessment bdi.

Eligibility criteria:
inclusion criteria: 1. diagnosis of panic disorder by dsm5 2. more than 18 years old 3. an essential ability to navigate smartwatch and mobile phone applications exclusion criteria: 1. current substance abuse 2. cardiopulmonary incapacity 3. incapacity or limited mental capacity 4. acute suicidal ideation

Keywords: wearables, case management, mobile-assisted care
rehabilitation of patient with acute isolated pcl rupture

Conditions: PCL

Summary: the posterior cruciate ligament injuries (pcl) is rare and rehabilitation methods are varying. the purpose of the study is to explore if one rehabilitation option is preferable to one other for patients with acute pcl injury, by examining whether there will be differences in laxity in the knee joints and patient-reported knee function by three different rehabilitation protocols. a randomized controlled trial with 75 patients enrolled will be followed up 3 and 12 months after injury. the groups will be compared using kneelaxity (stress - x) and subjective knee function (koos, ikdc-2000)

the posterior cruciate ligament injuries (pcl) is rare and rehabilitation methods are varying. the purpose of the study is to explore if one rehabilitation option is preferable to one other for patients with acute pcl injury, by examining whether there will be differences in laxity in the knee joints and patient-reported knee function by three different rehabilitation protocols. a randomized controlled trial with 75 patients enrolled will be followed up 3 and 12 months after injury. the groups will be compared using kneelaxity (stress - x) and subjective knee function (koos, ikdc-2000) to indicate whether one rehabilitation alternative is preferable in terms of less knee joint laxity and improve knee function. participants considered included in the study if he or she agrees to participate in the study by signing the informed consent. inclusion criteria will be whether the patient has an acute isolated pcl injury. exclusion is additional injuries of ligaments, cartilage and meniscus of the knee. randomization to groups is done continuously.

Eligibility criteria:
inclusion criteria: * acute isolated pcl injury : 0- 3 weeks ( maximum 21 days) from the initial injury * isolated pcl rupture (grade i, ii and iii) * patient age should be between 16-60 years ( with closed epiphyseal plate ) * understood and accepted written consent exclusion criteria: * injury to the acl or other ligaments in the knee * extensive injury to the cartilage or meniscus , requiring repairs * unfit to understand or to sign consent * history of alcohol or drug abuse in the past three years * current serious illness or injury that makes rehabilitation difficult.
systemic markers of collagen metabolism and vitamin c in smokers and non-smokers with pelvic organ prolapse

Conditions: Pelvic Organ Prolapse

Summary: data on smoking and pop are conflicting. in a study done by alnaif et al, smoking was found to be associated with severe pop. the authors' proposed explanation was that smoking impairs tissue and wound healing. our primary objective is to document whether smokers with pelvic organ prolapse (pop) are different from non-smokers with pop with respect to collagen biosynthesis and breakdown using systemic markers of collagen metabolism and vitamin c.

tissue destructive disorders are more common in smokers than in non-smokers. alterations in wound healing and connective tissue turnover are suggested mechanisms, but exact details remain to be discovered. the synthesis of subcutaneous collagen in smokers is specifically impeded, and that smokers have less collagen compared to non-smokers. jorgensen et al study showed that smokers tend to have less procollagen i n-propeptide (pinp) levels in the blood, less vitamin c and higher levels of matrix metalloproteinase (mmp-9), these findings reversed after smoking cessation. since smoking is one of the promoting and modifiable factors in the development of prolapse, understanding its effects on the support of pelvic organs may help modify the course of the pop condition in the future. understanding the connective tissue effects of smoking using systemic markers of collagen metabolism in female smokers with prolapse may help future management and counseling of these patients. in addition, description of the markers of collagen metabolism in pop has not previously been documented.

Eligibility criteria:
inclusion criteria: prolapse group * more than 18 years old * symptomatic pop at or beyond the hymen as determined by physical examination and a positive answer to the screening questions * for smoker group- smoke more than one pack per day * for non smoker group- non smoker for more than 7 years no prolapse group: * absence of prolapse and negative answer to the screening questions exclusion criteria: * using hormone replacement therapy (systemic estrogen, progesterone or testosterone) * using vaginal estrogen (cream, ring, tablet) * chronic steroid use * past medical history of connective tissue disease * scurvy, malabsorption, alcoholism, pregnancy, hyperthyroidism, liver disease and renal failure

Keywords: pelvic organ prolapse smoking and collagen metabolism
a study of clofarabine in combination with etoposide and cyclophosphamide in children with acute leukemias.

Conditions: Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Relapsed Leukemia

Summary: clofarabine (injection) is approved by the food and drug administration (fda) for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia (all) who have had at least 2 prior treatment regimens. this use is based on the induction of complete responses. randomized trials demonstrating increased survival or other clinical benefit have not been conducted. the purpose of the phase 1 portion of this study was to determine if clofarabine added to a combination of etoposide and cyclophosphamide is safe in children with relapsed or refractory acute lymphoblastic leukemia (all) or acute myelogenous leukemia (aml). the purpose of the phase 2 portion of the study was to measure the effectiveness of the combination therapy in children with all.


Eligibility criteria:
inclusion criteria: * note: the following eligibility criteria were applicable to acute lymphoblastic leukemia (all) and acute myelogenous leukemia (aml) patients for the phase 1 portion of this study, and to all patients for the phase 2 portion of the study (only all patients were allowed in the phase 2 portion of the study). * all with \> 25% blasts in bone marrow; aml with ≥ 5% blasts in bone marrow; all and aml patients may have extramedullary disease * karnofsky performance status ≥ 50 for patients \> 10 years old; lansky performance status ≥ 50 for patients ≤ 10 years old * prior therapy: aml: 1-2 prior induction regimens and ≤ 1 hematopoietic stem cell transplant (hsct); all: 1-3 prior induction regimens * adequate liver, renal, pancreatic, and cardiac function * have received no prior hsct (study amended in phase 2 to exclude patients with prior hsct) exclusion criteria: * note: the following eligibility criteria were applicable to all and aml patients for the phase 1 portion of this study, and to all patients for the phase 2 portion of the study (only all patients were allowed in the phase 2 portion of the study). * burkitt's leukemia * previous treatment with clofarabine * uncontrolled systemic fungal, bacterial or other infection and 48 hrs negative blood cultures required for patients with a history of fever within 3 days of enrollment * active cns involvement (i.e., should be cns1 or cns2) * inadequate time since last therapy: ≤ 14 days since last cytotoxic chemotherapy; ≤ 7 days since last biologic therapy; ≤ 14 days since last monoclonal antibody therapy * have received prior hsct (study amended in phase 2 to exclude patients with prior hsct) * pregnant or lactating * have tested positive for hepatitis b or hepatitis c infection or history of cirrhosis

Keywords: clofarabine acute leukemia all aml clolar clo218
biomarker analysis in sorafenib treated hepatocellular carcinoma patients

Conditions: Hepatocellular Carcinoma

Summary: to explore biomarkers predictive of clinical response to sorafenib in unresectable hepatocellular carcinoma using the prometheus platform to analyze expression and activation status of receptor tyrosine kinases in signal transduction pathways in fna samples and circulating tumor cells. to identify negative predictive markers to sorafenib. to elucidate signal transduction pathway attributable to sorafenib resistance. to monitor changes in the rtk activation status during sorafenib treatment using circulating tumor cells. to analyze correlation between the quantity of circulating tumor cells and circulating endothelial cell precursors and treatment response to sorafenib.


Eligibility criteria:
inclusion criteria: * patients with histologically confirmed hepatocellular carcinoma (hcc) or a combination of radiologically compatible finding to hcc, alpha-fetoprotein \> 400ng/ml and liver cirrhosis * inoperable disease as defined by (localized disease in a portion of the liver that doses not allow the possibility of complete surgical removal of the tumor with a clear resection margin or presence of extra-hepatic disease or main portal vein or hepatic vein involvement (invasion or tumor thrombus) or the hcc must not be amenable to intra-arterial therapy or local ablative therapy) * minimum life expectancy of 12 weeks * age \> 18 years. * ecog performance status of ≤ 2 * adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening: (hemoglobin \> 9.0 g/dl,absolute neutrophil count\>1,500/mm3, platelet count\>75,000/μl,total bilirubin \< 1.5 times the upper limit of normal,alt and ast \< 5 x upper limit of normal,albumin ≥ 3g/dl,pt-inr/ptt \< 1.5 x upper limit of normal,serum creatinine \< 1.5 x upper limit of normal or creatinine clearance ≥ 50ml/min) * signed and dated informed consent before the start of specific protocol procedures. * fna will be performed in patients with feasible biopsy site exclusion criteria: * decompensated cirrhosis or stage c (index \> 10) according to the child-pugh classification * other concomitant anticancer agent, including tamoxifen and interferon * active clinically serious infections (\> grade 2 ctcae version 3.0) * history of organ allograft * patients with evidence or history of bleeding diasthesis * patients undergoing renal dialysis * radiotherapy during study or within 4 weeks of start of study drug. * prior exposure to the study drug. * substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
screening for high-risk chronic obstructive pulmonary disease

Conditions: High-risk COPD

Summary: this study is a multicenter cross-sectional study design aimed at screening risk factors for the combination of disease and syndrome in high-risk individuals with chronic obstructive pulmonary disease (copd).

targeting high-risk populations for chronic obstructive pulmonary disease (copd), targeted at key issues such as unclear risk factors and lack of prevention and treatment plans, high-risk population screening was conducted to identify risk factors. this study is expected to detect at least 3600 high-risk individuals with early-stage chronic obstructive pulmonary disease. the incidence rate of high-risk individuals in the early stage of chronic obstructive pulmonary disease is 30%, which means the total screening population is 12000 cases.

Eligibility criteria:
inclusion criteria: * according to the diagnosis and treatment guidelines for chronic obstructive pulmonary disease (revised in 2021), a multi-stage cluster random sampling method was used to select individuals from representative administrative villages with a history of chronic cough or sputum production, breathing difficulties, recurrent lower respiratory tract infections, and/or exposure to potential risk factors for chronic obstructive pulmonary disease. * the investigators agreed to participate in this clinical study by voluntarily signing an informed consent form. exclusion criteria: * patients who are delirious, have impaired consciousness, dementia, various psychiatric disorders, etc., and cannot be accurately informed of their basic physical condition. * patients who, in the opinion of the investigator, are not suitable for participation in this study.

Keywords: high-risk copd scale
natural history study of pyruvate dehydrogenase deficiency

Conditions: Pyruvate Dehydrogenase Complex Deficiency; Pyruvate Dehydrogenase E1 Alpha Deficiency; Pyruvate Dehydrogenase E1-Beta Deficiency; Pyruvate Dehydrogenase E2 Deficiency; Pyruvate Dehydrogenase Phosphatase Deficiency

Summary: pyruvate dehydrogenase (pdh) deficiency is one of the most common mitochondrial disorders. patients with this genetic condition have difficulty utilising carbohydrates to produce energy and develop a combination of problems including seizures, poor balance, developmental delay, disability and have a reduced life expectancy. as for most mitochondrial disorders there is a lack of effective treatments. it is essential to understand the mechanisms underlying the disease in order to identify new treatments, and to understand the natural history of disease in order to prepare for clinical trials. to date, a natural history study of pdh deficiency has not been undertaken in the uk. the researchers aim to undertake the first natural history study of pdh deficiency in the uk, to describe the spectrum of symptoms, genetics, management and outcomes in both children and adult patients.


Eligibility criteria:
inclusion criteria: 1. compatible clinical history and 2a enzymatic confirmation demonstrating reduced pdh activity in patient cells or muscle tissue or 2b confirmed pathogenic mutation in a gene associated with primary pdh deficiency (pdha1, pdhb, pdhx, pdp1, dlat) or 2c first degree relative with a confirmed pathogenic mutation causing primary pdh deficiency exclusion criteria: patients with 'secondary pdh deficiency' that is patients who meet criteria 1 and 2a but who have received a genetic diagnosis which confirms pathogenic variants in a gene not associated with primary pdh deficiency.

Keywords: pdh deficiency natural history outcomes prognosis genotype-phenotype correlation quality of life outcome measures
study of patients admitted to a cardiac intensive care unit with acute cardiovascular disease

Conditions: Cardiogenic Shock; Acute Decompensated Heart Failure; Acute Pulmonary Embolism; Acute Myocardial Infarction

Summary: this is a registry of the patients that are admitted to cicu and treated by the scientific staff of the 2nd department of cardiology, due to an acute cardiovascular disease (acute coronary syndrome, acute heart failure, arrhythmia, pulmonary embolism, cardiac tamponade etc) in order to investigate the clinical characteristics of the patients, their outcome, identify the factors that could predict the in-hospital mortality and compare the results with the predicted by established risk scores. furthermore, the study will investigate the one-year mortality and also the major adverse cardiac events (mace - acute myocardial infarction, stroke, or cardiovascular death) will be measured.

for every patient that will be enrolled to the study, information from the medical record will be collected, as long as he/she has provided a signed consent form after being fully informed of the study and its objectives. in case the patient cannot decide on his/her own, e.g. intubated patients, an informed consent form must be acquired by a relative or legal representative. only the data that will be considered necessary for scientific reasons will be acquired: general and demographic information, medical information like the personal and family history, the diagnostic tests performed and the treatments or interventions that took place. the patients will not have to do anything further or undergo any additional visits or medical exams apart from those indicated; they will not receive any extra treatment (because of their participation to the study) beyond what they would receive for their condition according to the established practice so far. furthermore, the doctor will not change or withdraw any treatment that the patients would normally receive. the patients' medical care will continue normally under the cicu doctors' supervision. the participants will be monitored during their hospitalization in the cicu, during their hospitalization in the 2nd department of cardiology of the uhi after their discharge from cicu, as well as for the next 1-year in the outpatients clinic; if the latter is not feasible (in case of disability or distance) they will be contacted through telephone interviews.

Eligibility criteria:
inclusion criteria: * all patients admitted to the cardiac intensive care unit (cicu) through the emergency department of the uhi * all patients transferred to the cicu from other hospital departments or other regional secondary hospitals * patients with an acute cardiovascular disease that requires treatment in a cicu * patients who are under scientific supervision of the 2nd department of cardiology * patients (or their relative/legal representatives) that have signed the informed consent form exclusion criteria: none